Skip to content

Evaluation of efficacy of topical Naloxone® in control of neurotic pruritus

Evaluation of efficacy and safety of topical naloxone in control of chronic pruritus in patients with neurodermatitis

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT201702231165N18
Enrollment
70
Registered
2017-05-28
Start date
2017-03-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodermatitis. Neurotic excoriation

Interventions

Intervention 1: Control group: Patients in the control group will receive topical placebo formulation, twice daily (morning and evening) for a period of four weeks. Intervention 2: Intervention group
Placebo
Treatment - Drugs
Control group: Patients in the control group will receive topical placebo formulation, twice daily (morning and evening) for a period of four weeks.
Intervention group: The Patients in the treatment group will receive topical formulation of Naloxone® on the affected areas, twice a day (morning and evening) for a period of four weeks.

Sponsors

Baqiyatallah University of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
70 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: The patient has no addiction; have not been treated with any form of topical steroids; diagnosis of neurodermitis has been confirmed by a physician; the content form should have been completed by the patient; age between 25 and 65 years; have no other skin disorders; accessible at all times during the trial; do not leave the treatment after one week; do not have allergy to the medication. Exclusion criteria: when disease become uncontrollable; severe reaction or allergy to the medication; patients’ age less the 25 and more than 65 years

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of itching area. Timepoint: Before intervention; after intervention. Method of measurement: Standard Questionaries.;Distribution of itching area. Timepoint: Before intervention; after intervention. Method of measurement: Standard Questionaries.;Quality of life. Timepoint: Before intervention; after intervention. Method of measurement: Standard questionaries.

Secondary

MeasureTime frame
Itching Freqency. Timepoint: Before intervention; After intervention. Method of measurement: Standard Questionaries.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Yunes Panahi

Baqiatallah University of Medical Science

YUNESPANAHI@YAHOO.COM+98 21 8821 1524

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026